OseqTM Hereditary Cancer Panel (HCP) is a hereditary cancer assay that analyzes known and emerging tumor biomarkers for 17 cancer types. It has enabled BRCA testing for the first nationwide germline BRCA mutation prevalence study in Chinese ovarian cancer patients and multiple Poly ADP-Ribose Polymerase inhibitor (PARPi) Phase III global clinical studies.
Features and Benefits
| Broad Access to Accurate BRCA Variants for Chinese Patients |
|
||||||||
| Secure Highly Reliable Results |
|
||||||||
| Save Time, Money and Samples |
|
We care for your samples from receipt to the reporting of results. Highly experienced laboratory professionals follow strict quality procedures to ensure the integrity of your results.
Send us a no obligation request for quote and our dedicated sales team will reply to you within 24 hours.
Create a myBGI account to view all our sample and shipping documentation and to manage your project moving forwards. It's quick, free and easy!
Sequencing for the Oseq™ Hereditary Cancer Panel is available with DNBseq™ Next Generation Sequencing technology or Illumina HiSeq systems.
NimbleGen SeqCap, BGI designed, probe-based panel kit for library construction and enrichment
100bp Paired-end sequencing
Data analysis and mutations are interpreted with proprietary BGI database (Hereditary Cancer Genetic Database V1.0)
Results are delivered in standard file formats, including optional .vcf and .fastq formats for variants and raw sequencing data
Custom reports are available upon request
Reports and data are made available via secure FTP, AWS Cloud transfer or encrypted hard drive
Guaranteed ≥85% of bases with quality score of ≥Q30
Sequencing depth ≥300X
99.9% Accuracy, with Sanger sequencing or qPCR validation of positive NGS result
Typical 15 working days from sample QC acceptance to data analysis results availability
Expedited services are available, contact your local BGI specialist for details
The Oseq™ Hereditary Cancer Panel is cleared as a clinical test in China and is pending IVD approval through the China National Medical Products Administration (NMPA).
The Oseq™ Hereditary Cancer Panel is available as a clinically-validated Laboratory Developed Test (LDT) from BGI’s CLIA-certified and CAP-accredited service laboratory in Hong Kong.
Several data reporting options are available to tailor the Oseq™ Hereditary Cancer panel report to your specific needs. Contact your BGI representative for a full, current gene list.
| Reporting Options | Reported Genes | Reported Variants |
| Option 1 | BRCA1, BRCA2 | SNV, Indel (<20bp) and CNV from entire exon regions of genes in the panel. The full panel size is 836 kb and total number of exons is 1730 |
| Option 2 | BRCA1, BRCA2, plus 25 genes related to hereditary risk of ovarian and breast cancer | |
| Option 3 | BRCA1, BRCA2, plus 49 genes for 16 types of cancer related to hereditary risk, including: • Ovarian cancer • Gastric cancer • Renal carcinoma • Prostate cancer • Multiple endocrine neoplasia • Thyroid cancer • Parathyroid carcinoma • Neurofibromatosis • Pheochromocytoma • Familial paraganglioma • Retinoblastoma • Melanoma • Chondrosarcoma • Colorectal cancer • Pancreatic cancer • Endometrial cancer |
|
| Option 4 | Comprehensive report on all 115 genes included in the full panel.These 39 additional genes have been reported to play a role in hereditary cancers and can be used for research purposes. |
We can process your Blood, Saliva or DNA samples with the following general requirements:
| Sample type | Sample Requirement |
| Whole blood | • 5ml, using EDTA anticoagulant tube • Shipping at ambient temperature |
| Saliva | • ≥ 2ml saliva with using DNA Genotek collection kit • Shipping at room temperature |
| DNA | • Concentration ≥ 30ng/μl • Total Mass ≥ 1μg • OD260/280: 1.8-2.0 • Shipping with dry ice |
